|Day's Range||3.76 - 3.76|
|52 Week Range||0.00 - 4.97|
|PE Ratio (TTM)||-0.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Generex Biotechnology Corporation today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of the open of the market on March 14, 2017, the Company’s common stock will begin trading on a split-adjusted basis.
Generex Biotechnology Corporation today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his management team, tomorrow, Wednesday, February 22, 2017, at 10 am.
Generex Biotechnology Corporation today announced that it has achieved the elimination of its outstanding derivative securities.